New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 20, 2014
09:24 EDTPRGO, TEVAPerrigo announces settlement in Proair HFA patent case
Perrigo (PRGO) and its partner, Catalent, announced that they have settled their first to file Hatch Waxman litigation with Teva (TEVA) with respect to a generic version of Proair HFA. Pursuant to the settlement, Perrigo has a limited quantity license to launch a generic version of Proair HFA starting on December 19, 2016 and an unlimited quantity license beginning after June 30, 2018. Proair® HFA indicated in patients 4 years of age and older for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm. Brand sales were approximately $1.4B over the last 52-weeks according to Symphony Health Solutions.
News For PRGO;TEVA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 5, 2015
11:30 EDTTEVATeva volatility at low end of range on tight price movement
Teva March call option implied volatility is at 22, April and June is at 20, September is at 21; compared to its 26-week average of 23, suggesting decreasing near term price movement.
08:31 EDTTEVAANI Pharmaceuticals acquires generic drug product from Teva
ANI Pharmaceuticals (ANIP) announced that it has acquired the approved abbreviated new drug application for Flecainide Acetate tablets USP 50mg, 100mg and 150mg, previously marketed by Teva Pharmaceuticals (TEVA). According to IMS Health, the overall market for this product was approximately $39M in 2014. ANI has forty-seven generic drug products under development addressing a total annual market size of approximately $3B, based on data from IMS Health.
March 3, 2015
06:14 EDTPRGOPerrigo investor sentiment could improve this year, says Deutsche Bank
Deutsche Bank believes Perrigo investor sentiment remains poor and says it "wouldn't wait for things to look perfect" to buy the stock. Deutsche thinks a return to consistent financial results, earnings growth acceleration in Q2 following the close of the Omega acquisition, and a possible investor day around May 5 could drive improved sentiment on the name. It lowered its price target for Perrigo shares to $200 from $204 and keeps a Buy rating on the stock.
March 2, 2015
08:24 EDTTEVATeva announces sale of Sellersville, PA facility to G&W Laboratories
Subscribe for More Information
07:20 EDTTEVACowen to hold a conference
Subscribe for More Information
February 25, 2015
08:05 EDTTEVATeva says FDA accepts CEP-33237 NDA for review
Subscribe for More Information
February 24, 2015
09:02 EDTTEVATeva announces phase 2b study of TEV-48125 achieved endpoints
Subscribe for More Information
February 23, 2015
15:04 EDTTEVATeva announces publication of data on Phase III trials of reslizumab
Subscribe for More Information
February 20, 2015
08:04 EDTTEVATeva to present new respiratory data at AAAAI
Teva Pharmaceutical Industries announced that four company-sponsored abstracts will be presented at the 2015 Annual Meeting of the American Academy of Allergy, Asthma and Immunology, or AAAAI, in Houston, Texas. Data to be presented include two replicate 52-week Phase III global studies of the company’s anti-IL5 monoclonal antibody, reslizumab, in patients with asthma and elevated blood eosinophils who were inadequately controlled on medium-to-high doses of inhaled corticosteroids with or without an additional controller. The data are scheduled for presentation on Monday, February 23 during an oral session titled “Asthma Therapy and Mechanisms.” Also to be presented are two Phase III studies of beclomethasone dipropionate 40mcg, which gained FDA approval in December 2014, and is now available for the treatment of nasal symptoms associated with allergic rhinitis in children 4-11 years of age. In addition, a dose-response study evaluating the safety and efficacy of fluticasone/salmeterol multidose dry-powder inhaler in patients 12 years of age and older with persistent asthma will be presented.
07:08 EDTTEVA, PRGOAmerican Academy of Allergy, Asthma and Immunology to hold annual meeting
2015 Annual Meeting of AAAAI is being held in Houston, Texas on February 20-24.
February 19, 2015
17:03 EDTTEVATeva to initiate Phase 2b TV-45070 clinical trial
Xenon Pharmaceuticals (XENE) announced that its development and commercialization partner Teva Pharmaceutical (TEVA) will initiate a Phase 2b clinical trial of TV-45070 in patients with post-herpetic neuralgia, or PHN. The Phase 2b clinical trial in PHN will be a randomized, double-blind, placebo controlled, multi-site study to evaluate the efficacy and safety of TV-45070 in patients with PHN. The study will include three treatment groups to receive doses of 4% or 8% of TV-45070 or placebo, dosed twice daily. Approximately 330 patients will be enrolled in the study. Patients will be stratified into treatment groups based on their R1150W status, a genetic pain biomarker believed to be related to pain susceptibility. The primary endpoint of this study is the change from baseline to week 4 in the numeric rating scale, or NRS, scores. Secondary endpoints include additional pain measurement scores at specified daily time points, the percentage of patients with greater than 30% and greater than 50% improvement in pain scores, quality of life measurements and adverse events measurements. The first patient is anticipated to be dosed in March, and the anticipated completion date for the Phase 2b clinical trial is mid-2016.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use